About DUAKLIR

Clear the Pathway to What's Possible With DUAKLIR

The twice-daily dosing of Duaklir® Pressair® provides your patients with improved lung function in the morning and evening, which may help them rediscover their ability to do normal, everyday activities, all day long.2

Give every breath potential with DUAKLIR PRESSAIR.

Your Patients Don’t Have to Settle for a Diminished Quality of Life Due to COPD

DUAKLIR is an effective LAMA/LABA medication that improves breathing and has demonstrated improvement in quality of life as measured by St. George's Respiratory Questionnaire (SGRQ).4

The SGRQ is a patient-reported, respiratory disease-specific instrument designed to measure:5

Day/Night Activities

Impact on Daily Life

Symptoms

Upward arrow icon with 50%

More Patients

Achieved clinically meaningful improvement* in health-related quality of life for patients taking DUAKLIR vs placebo.6

The SGRQ responder rate at week 24 for DUAKLIR was 58% compared to 39% with placebo odds ratio of 2.3 (95% Cl: 1.4, 3.6).

*Defined as a ≥4-unit improvement from baseline.
†DUAKLIR vs placebo did not meet statistical significance in two other phase 3 clinical trials.
A pooled analysis of ACLIFORM and AUGMENT.
Cl=confidence interval.

Dual Bronchodilators for Improved Benefits*

DUAKLIR combines long-acting aclidinium bromide with formoterol fumarate—providing your patients with powerful dual bronchodilation, taken twice daily for full 24-hour symptom control.2

DUAKLIR PRESSAIR Dual Bronchodilators

 

*Benefits are defined as improvement in lung function of one bronchodilator vs two bronchodilators

†DUAKLIR is not indicated for the initial treatment of acute episodes of bronchospasm and does not replace the use of rescue inhalers.

Patient standing next to icon of clock

COPD Is an Around-the-Clock Symptomatic Disease

Despite regular treatment, over 90% of patients with stable COPD experience symptoms at some point during the day, with the most troublesome times of the day being early morning and nighttime.7

Clinical2,8

Nighttime symptoms or awakenings

Shortness of breath

Chronic cough

Emotional7

Defeated in how COPD has affected their daily lives and the activities they used to do

Helpless as their sphere of activities continues to shrink due to COPD

Indication and Usage

DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

  • DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is only indicated for use in COPD and is not indicated for use in asthma. Use of a long-acting beta2-adrenergic agonist (LABA) as monotherapy, including formoterol fumarate, one of the active ingredients in DUAKLIR PRESSAIR, without an inhaled corticosteroid (ICS) is contraindicated in patients with asthma and increases the risk of asthma-related death. When LABA are used in fixed-dose combinations with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared to ICS alone.
  • DUAKLIR PRESSAIR is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to aclidinium bromide or formoterol fumarate or any component of the product
  • DUAKLIR PRESSAIR is not indicated for the treatment of acute episodes of bronchospasm (i.e. rescue therapy)
  • Do not initiate DUAKLIR PRESSAIR with an additional medicine containing a LABA because of risk of overdose or in acutely deteriorating COPD
  • Immediate hypersensitivity reactions, including anaphylaxis, angioedema (swelling of lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have occurred after administration of DUAKLIR PRESSAIR. Additionally, inhaled medicines, including DUAKLIR PRESSAIR, may cause paradoxical bronchospasm which may be life threatening. If any of these occurs, immediate treatment with a short acting bronchodilator should be initiated and treatment with DUAKLIR PRESSAIR should be stopped and alternative therapy initiated
  • DUAKLIR PRESSAIR should be used with caution in patients with cardiovascular and convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, hypokalemia, hyperglycemia, narrow-angle glaucoma or urinary retention. Instruct patients to consult a physician immediately should any signs or symptoms of acute narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction develop
  • The most common adverse reactions (≥3% incidence and more common than placebo) were upper respiratory tract infection (8.9% vs 6.3%), headache (6.3% vs 5.1%), and back pain (3.8% vs 3.4%) for DUAKLIR PRESSAIR vs placebo, respectively. Other adverse reactions reported in clinical studies (>1% but less than 3% and more common than placebo) with DUAKLIR PRESSAIR were cough, sinusitis, influenza, tooth abscess, insomnia, dizziness, dry mouth, oropharyngeal pain, muscle spasm, musculoskeletal pain, arthralgia, pain in extremity, urinary tract infection, and increased blood creatine phosphokinase

Medical Information

For answers to your medical questions about DUAKLIR PRESSAIR, please contact Circassia Medical Information at medinfo.us@circassia.com.

Please also see the full Prescribing Information, including Patient Information.

  • DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is only indicated for use in COPD and is not indicated for use in asthma. Use of a long-acting beta2-adrenergic agonist (LABA) as monotherapy, including formoterol fumarate,
  • DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is only indicated for use in COPD and is not indicated for use in asthma. Use of a long-acting beta2-adrenergic agonist (LABA) as

Indication and Usage

DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

  • DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is only indicated for use in COPD and is not indicated for use in asthma. Use of a long-acting beta2-adrenergic agonist (LABA) as monotherapy, including formoterol fumarate, one of the active ingredients in DUAKLIR PRESSAIR, without an inhaled corticosteroid (ICS) is contraindicated in patients with asthma and increases the risk of asthma-related death. When LABA are used in fixed-dose combinations with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared to ICS alone.
  • DUAKLIR PRESSAIR is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to aclidinium bromide or formoterol fumarate or any component of the product
  • DUAKLIR PRESSAIR is not indicated for the treatment of acute episodes of bronchospasm (i.e. rescue therapy)
  • Do not initiate DUAKLIR PRESSAIR with an additional medicine containing a LABA because of risk of overdose or in acutely deteriorating COPD
  • Immediate hypersensitivity reactions, including anaphylaxis, angioedema (swelling of lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have occurred after administration of DUAKLIR PRESSAIR. Additionally, inhaled medicines, including DUAKLIR PRESSAIR, may cause paradoxical bronchospasm which may be life threatening. If any of these occurs, immediate treatment with a short acting bronchodilator should be initiated and treatment with DUAKLIR PRESSAIR should be stopped and alternative therapy initiated
  • DUAKLIR PRESSAIR should be used with caution in patients with cardiovascular and convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, hypokalemia, hyperglycemia, narrow-angle glaucoma or urinary retention. Instruct patients to consult a physician immediately should any signs or symptoms of acute narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction develop
  • The most common adverse reactions (≥3% incidence and more common than placebo) were upper respiratory tract infection (8.9% vs 6.3%), headache (6.3% vs 5.1%), and back pain (3.8% vs 3.4%) for DUAKLIR PRESSAIR vs placebo, respectively. Other adverse reactions reported in clinical studies (>1% but less than 3% and more common than placebo) with DUAKLIR PRESSAIR were cough, sinusitis, influenza, tooth abscess, insomnia, dizziness, dry mouth, oropharyngeal pain, muscle spasm, musculoskeletal pain, arthralgia, pain in extremity, urinary tract infection, and increased blood creatine phosphokinase

Medical Information

For answers to your medical questions about DUAKLIR PRESSAIR, please contact Circassia Medical Information at medinfo.us@circassia.com.

Please also see the full Prescribing Information, including Patient Information.

REFERENCES: 1. Loveridge B, et al. Am Rev Respir Dis. 1986;134(5):930-934. 2. Duaklir® Pressair® (aclidinium bromide/formoterol fumarate inhalation powder)[prescribing information]. Morrisville, NC: Circassia Pharmaceuticals Inc; 2019. 3. Sethi S, et al. International Journal of COPD. 2019;14:667-682. 4. Data on file, Circassia. 5. Jones PW, et al. Respir Med. 1991;85(suppl B):25-31. 6. D'Urzo AD, et al. Respir Res. 2014;15:123. 7. Miravitlles M, et al. Respir Res. 2014;15:122. 8. Balachandran J, et al. Am J Respir Grit Care Med. 2013;188:5-6. 9. Singh D, et al. BMC Pulmonary Medicine. 10. Cote CG, et al. Chest. 2008;134:104001. 11. Wise RA, et al. JAMA. 2019;321(17):1693-1701. 12. Tudorza® Pressair® (aclidinium bromide inhalation powder) [prescribing information]. Morrisville, NC: Circassia Pharmaceuticals Inc; 2019. 13. Ocakli B, et al. Int J Chron Obstruct Pulmon Dis. 2018;13:2941-2947. 14. Centers for Disease Control and Prevention. Chronic Obstructive Pulmonary Disease Among Adults – United States, 2011. MMWR. Nov 2012;61(46);938-943. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6146a2.htm?s_cid=mm6146a2_w. Accessed April 7, 2016. 15. Centers for Disease Control and Prevention. Deaths: Leading Causes for 2017. National Vital Statistics Reports. 2019;68(6). https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_06-508.pdf. Published June 24, 2019. Accessed August 19, 2019. 16. National Heart, Lung, and Blood Institute (NHLBI). Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. http://www.nhlbi.nih.gov/files/docs/research/2012_ChartBook_508.pdf. Published February 2012. Accessed April 7, 2016. 17. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Updated November 2018. Accessed July 16, 2019. 18. Ford ES, Croft JB, Mannino DM, Wheaton AG, Zhang X, Giles WH. COPD Surveillance–United States, 1999-2011. Chest. 2013;144(1):284-305. 19. Chronic Obstructive Pulmonary Disease (COPD) Includes: Chronic Bronchitis and Emphysema. National Center for Health Statistics website. https://www.cdc.gov/nchs/fastats/copd.htm. Updated May 3, 2017. Accessed July 16, 2019. 20. American Lung Association. What Causes COPD. http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/copd/symptoms-causes-risk-factors/what-causes-copd.html. Published 2016. Accessed April 7, 2016. 21. World Health Organization. Causes of COPD. http://www.who.int/respiratory/copd/causes/en/#. Accessed April 7, 2016.